Authors:
Wu, AW
Fink, NE
Cagney, KA
Bass, EB
Rubin, HR
Meyer, KB
Sadler, JH
Powe, NR
Citation: Aw. Wu et al., Developing a health-related quality-of-life measure for end-stage renal disease: The CHOICE Health Experience Questionnaire, AM J KIDNEY, 37(1), 2001, pp. 11-21
Authors:
Miskulin, DC
Athienites, NV
Yan, G
Martin, AA
Ornt, DB
Kusek, JW
Meyer, KB
Levey, AS
Citation: Dc. Miskulin et al., Comorbidity assessment using the Index of Coexistent Diseases in a multicenter clinical trial, KIDNEY INT, 60(4), 2001, pp. 1498-1510
Authors:
Athienites, NV
Miskulin, DC
Fernandez, G
Bunnapradist, S
Simon, G
Landa, M
Schmid, CH
Greenfield, S
Levey, AS
Meyer, KB
Citation: Nv. Athienites et al., Comorbidity assessment in hemodialysis and peritoneal dialysis using the index of coexistent disease, SEMIN DIAL, 13(5), 2000, pp. 320-326
Authors:
Cagney, KA
Wu, AW
Fink, NE
Jenckes, MW
Meyer, KB
Bass, EB
Powe, NR
Citation: Ka. Cagney et al., Formal literature review of quality-of-life instruments used in end-stage renal disease, AM J KIDNEY, 36(2), 2000, pp. 327-336
Citation: Kb. Meyer et Dah. Mufti, Post-transcriptional regulation of E2A proteins via lipopolysaccharide andCD40 signaling, EUR J IMMUN, 30(2), 2000, pp. 719-724
Authors:
Arora, P
Obrador, GT
Ruthazer, R
Kausz, AT
Meyer, KB
Jenuleson, CS
Pereira, BJG
Citation: P. Arora et al., Prevalence, predictors, and consequences of late nephrology referral at a tertiary care center, J AM S NEPH, 10(6), 1999, pp. 1281-1286
Citation: Kb. Meyer, Induction of the Ig chi 3 ' enhancer by distinct pathways can be inhibitedby cross-linking of the CD40 receptor, EUR J IMMUN, 29(3), 1999, pp. 872-877